Boston Scientific stock is down about 33% year-to-date, with a 9% single-session decline on March 30 driven by fresh trial data concerns. This drawdown marks a reversal for a company that has delivered consistent double-digit revenue growth over multiple years.

The CHAMPION-AF trial for the Watchman FLX device met endpoints but showed a slightly higher ischemic stroke rate versus blood thinners, prompting a downgrade and target cut to $88. While Q4 2025 revenue of $5.29 billion and EPS of $0.80 topped estimates, Q1 2026 guidance fell short of analyst expectations.

Boston Scientific has grown revenue at a 16.6% annual rate over three years, outpacing Medtronic’s 4.9% and Abbott’s 0.7%, with operating margins of 19.8% versus peers’ sub-19%. The balance sheet shows a low debt-to-equity ratio of 11.1% but a lean cash-to-assets ratio of 4.5%, contributing to heightened volatility on negative headlines.

The stock trades at 18.1x forward earnings, well below its three-year average of 26.5x; reverting to a 25x multiple would imply a share price near $87. That valuation shift suggests roughly 40% upside from current levels, aligning with the revised target and underscoring potential investor gains.